Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.7 CHF | +1.24% | +3.04% | +15.30% |
03/05 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
09/04 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.30% | 542M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Transcript : Basilea Pharmaceutica AG, 2023 Earnings Call, Feb 13, 2024